|
1
|
Kraaijeveld AO, de Jager SC, van Berkel
TJ, Biessen EA and Jukema JW: Chemokines and atherosclerotic plaque
progression: towards therapeutic targeting? Curr Pharm Des.
13:1039–1052. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roger VL, Go AS, Lloyd-Jones DM, et al;
American Heart Association Statistics Committee and Stroke
Statistics Subcommittee. Heart disease and stroke statistics - 2012
update: a report from the American Heart Association. Circulation.
125:e2–e220. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weber C, Zernecke A and Libby P: The
multifaceted contributions of leukocyte subsets to atherosclerosis:
lessons from mouse models. Nat Rev Immunol. 8:802–815. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koh KK: Combination treatment to prevent
atherosclerosis. Hypertension. 54:e10–e11. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tian J, Gu X, Sun Y, et al: Effect of
statin therapy on the progression of coronary atherosclerosis. BMC
Cardiovasc Disord. 12:702012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hoffmann H, Frieler K, Schlattmann P, Hamm
B and Dewey M: Influence of statin treatment on coronary
atherosclerosis visualised using multidetector computed tomography.
Eur Radiol. 20:2824–2833. 2010. View Article : Google Scholar
|
|
7
|
Ross R and Harker L: Hyperlipidemia and
atherosclerosis. Science. 193:1094–1100. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Inadera H and Hamazaki T: Cholesterol
controversy: cutoff point of low-density lipoprotein cholesterol
level in Guidelines by Japan Atherosclerosis Society. Nihon
Eiseigaku Zasshi. 65:506–515. 2010.(In Japanese).
|
|
9
|
Ravnskov U: High cholesterol level may
protect against infections and probably also atherosclerosis.
Lakartidningen. 101:1215–1217; discussion 1218, 1221–1222. 2004.(In
Swedish).
|
|
10
|
Nishizawa Y, Shoji T, Ishimura E, Inaba M
and Morii H: Paradox of risk factors for cardiovascular mortality
in uremia: is a higher cholesterol level better for atherosclerosis
in uremia? Am J Kidney Dis. 38(4 Suppl 1): S4–S7. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liuzzo G: Atherosclerosis: an inflammatory
disease. Rays. 26:221–230. 2001.
|
|
12
|
Navab M, Gharavi N and Watson AD:
Inflammation and metabolic disorders. Curr Opin Clin Nutr Metab
Care. 11:459–464. 2008. View Article : Google Scholar
|
|
13
|
Campbell KA, Lipinski MJ, Doran AC,
Skaflen MD, Fuster V and McNamara CA: Lymphocytes and the
adventitial immune response in atherosclerosis. Circ Res.
110:889–900. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gerrity RG, Naito HK, Richardson M and
Schwartz CJ: Dietary induced atherogenesis in swine. Morphology of
the intima in prelesion stages. Am J Pathol. 95:775–792.
1979.PubMed/NCBI
|
|
15
|
Gerszten RE, Mach F, Sauty A, Rosenzweig A
and Luster AD: Chemokines, leukocytes, and atherosclerosis. J Lab
Clin Med. 136:87–92. 2000. View Article : Google Scholar
|
|
16
|
Frieri M: Accelerated atherosclerosis in
systemic lupus erythematosus: role of proinflammatory cytokines and
therapeutic approaches. Curr Allergy Asthma Rep. 12:25–32. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takahashi M: Inflammatory cytokines in the
pathogenesis of atherosclerosis. Nihon Rinsho. 69:30–33. 2011.(In
Japanese).
|
|
18
|
Ait-Oufella H, Taleb S, Mallat Z and
Tedgui A: Recent advances on the role of cytokines in
atherosclerosis. Arterioscler Thromb Vasc Biol. 31:969–979. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morris JB, Olzinski AR, Bernard RE, et al:
p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic
iron oxide uptake in a mouse model of atherosclerosis: MRI
assessment. Arterioscler Thromb Vasc Biol. 28:265–271. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dąbek J, Kułach A and Gąsior Z: Nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB): a
new potential therapeutic target in atherosclerosis? Pharmacol Rep.
62:778–783. 2010.
|
|
21
|
Ortiz-Muñoz G, Martin-Ventura JL,
Hernandez-Vargas P, et al: Suppressors of cytokine signaling
modulate JAK/STAT-mediated cell responses during atherosclerosis.
Arterioscler Thromb Vasc Biol. 29:525–531. 2009.PubMed/NCBI
|
|
22
|
Kirii H, Niwa T, Yamada Y, et al: Lack of
interleukin-1beta decreases the severity of atherosclerosis in
ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 23:656–660.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Egorova MO: Increased serum level of the
acute inflammation phase parameter CRP and the high level of low
density lipoprotein cholesterol - factors of increased risk of
development of atherosclerosis and its complications (a literature
review). Klin Lab Diagn. 3–6. 2002.(In Russian).
|
|
24
|
Olson NC, Callas PW, Hanley AJ, et al:
Circulating levels of TNF-α are associated with impaired glucose
tolerance, increased insulin resistance, and ethnicity: the Insulin
Resistance Atherosclerosis Study. J Clin Endocrinol Metab.
97:1032–1040. 2012.
|
|
25
|
Haddy N, Sass C, Droesch S, et al: IL-6,
TNF-alpha and atherosclerosis risk indicators in a healthy family
population: the STANISLAS cohort. Atherosclerosis. 170:277–283.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zaritsky JJ and Kalantar-Zadeh K: The
crossroad of RAAS modulation, inflammation, and oxidative stress in
dialysis patients: light at the end of the tunnel? J Am Soc
Nephrol. 23:189–191. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ferrario C: Effect of angiotensin receptor
blockade on endothelial function: focus on olmesartan medoxomil.
Vasc Health Risk Manag. 5:301–314. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hershon KS: Mechanistic and clinical
aspects of renin-angiotensin-aldosterone system blockade in the
prevention of diabetes mellitus and cardiovascular disease. Endocr
Pract. 17:430–440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheng M, Wen R and Zhang CG: Supercritical
fluid extraction of fistular onion stalk by carbon dioxide. Herald
of Medicine. 27:213–215. 2008.(In Chinese).
|
|
30
|
Zhou BR, Pan Y and Zhai ZM: Fibrinogen and
P-selectin expression in atherosclerosis model of Sprague Dawley
rat. Chin Med J (Engl). 124:3768–3772. 2011.PubMed/NCBI
|
|
31
|
Fu Q, Liu J, Zhang C, et al: Separation
and identification of flavonoids from fistular onion stalk
(Allium fisturosum L. var. caespitosum Makino). J
Huazhong Univ Sci Technolog Med Sci. 30:255–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang JM, Hao JJ, Guo J, He BH and Huang
H: Effects of fistular onion stalk extract on the level of NO and
expression of endothelial NO synthase (eNOS) in human umbilical
vein endothelium cells. Afr J Biotechnol. 10:2536–2540. 2011.
|
|
33
|
Fotis L, Agrogiannis G, Vlachos IS, et al:
Intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion
molecule (VCAM)-1 at the early stages of atherosclerosis in a rat
model. In Vivo. 26:243–250. 2012.PubMed/NCBI
|
|
34
|
Fan J and Watanabe T: Inflammatory
reactions in the pathogenesis of atherosclerosis. J Atheroscler
Thromb. 10:63–71. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Libby P: Inflammation in atherosclerosis.
Nature. 420:868–874. 2002. View Article : Google Scholar
|
|
36
|
Paoletti R, Gotto AM Jr and Hajjar DP:
Inflammation in atherosclerosis and implications for therapy.
Circulation. 109(23 Suppl 1): III20–III26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fukui K, Yamada H and Matsubara H:
Pathophysiological role of tissue renin-angiotensin-aldosterone
system (RAAS) in human atherosclerosis. Nihon Rinsho. 70:1556–1561.
2012.(In Japanese).
|
|
38
|
Hirata Y, Fukuda D and Sata M: Critical
role of renin-angiotensin system in the pathogenesis of
atherosclerosis. Nihon Rinsho. 69:55–59. 2011.(In Japanese).
|
|
39
|
Partigulova AS and Naumov VG: Inflammation
and atherosclerosis: the role of Renin-Angiotensin system and its
inhibition. Kardiologiia. 50:50–55. 2010.(In Russian).
|
|
40
|
Fukuda D, Enomoto S, Nagai R and Sata M:
Inhibition of renin-angiotensin system attenuates periadventitial
inflammation and reduces atherosclerotic lesion formation. Biomed
Pharmacother. 63:754–761. 2009. View Article : Google Scholar
|
|
41
|
Lu H, Balakrishnan A, Howatt DA, et al:
Comparative effects of different modes of renin angiotensin system
inhibition on hypercholesterolaemia-induced atherosclerosis. Br J
Pharmacol. 165:2000–2008. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Monaco C, Andreakos E, Kiriakidis S, et
al: Canonical pathway of nuclear factor kappa B activation
selectively regulates proinflammatory and prothrombotic responses
in human atherosclerosis. Proc Natl Acad Sci USA. 101:5634–5639.
2004. View Article : Google Scholar
|
|
43
|
Gareus R, Kotsaki E, Xanthoulea S, et al:
Endothelial cell-specific NF-kappaB inhibition protects mice from
atherosclerosis. Cell Metab. 8:372–383. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gharavi NM, Alva JA, Mouillesseaux KP, et
al: Role of the Jak/STAT pathway in the regulation of interleukin-8
transcription by oxidized phospholipids in vitro and in
atherosclerosis in vivo. J Biol Chem. 282:31460–31468. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
O’Sullivan LA, Liongue C, Lewis RS,
Stephenson SE and Ward AC: Cytokine receptor signaling through the
Jak-Stat-Socs pathway in disease. Mol Immunol. 44:2497–2506.
2007.PubMed/NCBI
|
|
46
|
Recinos A III, LeJeune WS, Sun H, et al:
Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in
aortic adventitia of LDL receptor-deficient mice. Atherosclerosis.
194:125–133. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Muslin AJ: MAPK signalling in
cardiovascular health and disease: molecular mechanisms and
therapeutic targets. Clin Sci (Lond). 115:203–218. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mamani-Matsuda M, Kauss T, Al-Kharrat A,
et al: Therapeutic and preventive properties of quercetin in
experimental arthritis correlate with decreased macrophage
inflammatory mediators. Biochem Pharmacol. 72:1304–1310. 2006.
View Article : Google Scholar
|
|
49
|
Schültke E, Kendall E, Kamencic H, Ghong
Z, Griebel RW and Juurlink BH: Quercetin promotes functional
recovery following acute spinal cord injury. J Neurotrauma.
20:583–591. 2003.PubMed/NCBI
|
|
50
|
Rivera L, Morón R, Sánchez M, Zarzuelo A
and Galisteo M: Quercetin ameliorates metabolic syndrome and
improves the inflammatory status in obese Zucker rats. Obesity
(Silver Spring). 16:2081–2087. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kleemann R, Verschuren L, Morrison M, et
al: Anti-inflammatory, anti-proliferative and anti-atherosclerotic
effects of quercetin in human in vitro and in vivo models.
Atherosclerosis. 218:44–52. 2011. View Article : Google Scholar : PubMed/NCBI
|
